Jeffrey S. Yoshida, M.D.
Jeffrey S. Yoshida, M.D. recognizes that each of his patients carries a unique personality and background -- as does their cancer. For that reason, he believes that medical care should be customized and specific to the individual.
Dr. Yoshida received his medical degree from Loma Linda University. Soon after, he pursued a general surgery internship at Harbor-UCLA Medical Center, followed by a residency in urology at Loma Linda. He completed a laparoscopic oncology/robotic surgery fellowship at City of Hope, where he was the first fellow ever to be trained in robotic surgery.
Before becoming City of Hope Orange County’s medical director of urologic surgery, Dr. Yoshida held a position as associate clinical professor at City of Hope. He also worked at Hoag Family Cancer Institute as the medical director of urologic oncology, where he was honored with an endowed chair in urologic oncology.
Today, Dr. Yoshida is excited to use the latest advances in robotic surgery and molecular imaging to ensure his patients receive the best care possible. He continues to earn renown as an expert in this gentler approach to removing tumors, which typically offers patients fewer side effects and faster recovery compared to open procedures.
In his spare time, Yoshida enjoys surfing and spending time with his family and their dog.
Care at City of Hope Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Newport Beach
Newport Beach, CA 92660
- 1996, M.D., Loma Linda University, Loma Linda, CA
- 1992, B.S., Biology, summa cum laude, Pacific Union College, Angwin, CA
- 2003-2004, Laparoscopic Oncology/Robotic Surgery, City of Hope, Duarte, CA
- 1997-2003, Urology, Loma Linda University, Loma Linda, CA
- 1996-1997, General Surgery, Harbor-UCLA, Los Angeles, CA
- 2022-present, Medical Director of Urologic Surgery; Assistant Clinical Professor, Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Orange County
- 2008-2022, Medical Director Urologic Oncology, Hoag Family Cancer Institute, Hoag Hospital, Newport Beach, CA
- 2004-2008, Associate Clinical Professor, Urologic Oncology, City of Hope, Duarte, CA
- Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 2016
- In-bore Magnetic Resonance-Guided Biopsy for the detection of Clinically Significant Prostate Cancer. Abdominal Radiology Apr 2016
- Impact of NADiA ProsVue PSA Slope on Secondary Treatment Decisions after Radical Prostatectomy. Nature (submitted for publication).
- Performance of a single assay for both type III and type IV TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem. 54(12):2007-17, Dec 2008
- Assessment of low prostate weight as a determinant of a higher positive margin rate after radical prostatectomy:a prospective pathologic study of 1500 cases. Surg Endosc. 23(5):1058-64, May 2009
- The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy. J Urol. 2008 Sep; 180(3):928-32.
- Robotic Surgery. Kidney Cancer Journal 2008
- Vaccinia Virus Mediated p53 Gene Therapy for Bladder Cancer in Orthotopic Murine Model. J Urol 173(4):604, Feb 2005
- Urinary Function Quality of Life After Laparoscopic or Robotic Assisted Radical Prostatectomy. J Urol 171(4):145, May 2004